Myocardial necrosis in patients with thrombotic thrombocytopenic purpura: pathophysiology and rationale for specific therapy.
Myocardial necrosis is now recognized as a common feature of thrombotic thrombocytopenic purpura (TTP), usually due to platelet plugging in the microvasculature. Despite reports that TTP patients with myocardial damage have higher morbidity and mortality, there are no established guidelines for managing these high-risk patients. The universal occurrence of thrombocytopenia and variable findings including renal dysfunction present unique challenges in this setting. Established therapies including plasma exchange and immunosuppression are the mainstay of therapy for all TTP patients. For the subset of patients with myocardial damage, therapy with more potent antiplatelet drugs, agents that enhance NO availability and alleviate vasospasm and drugs that suppress von Willebrand factor levels may have additional benefit. However, clinical trials are needed to optimize therapy for this subset of TTP patients.
Sane
David C
DC
Section on Cardiology, Department of Internal Medicine, Wake Forest University, School of Medicine, Winston-Salem, NC 27157-1082, USA. dsane@wfubmc.edu
Streer
Nathan P
NP
Owen
John
J
D006331:Heart Diseases / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D009206:Myocardium / Q000473:pathology*; D009336:Necrosis; D011696:Purpura, Thrombocytopenic / Q000150:complications* / Q000503:physiopathology / Q000628:therapy